Results 271 to 280 of about 35,120,764 (296)

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Journal of Thoracic Oncology, 2021
Noriko Motoi, Hidehito Horinouchi, Masayuki Shirasawa   +2 more
exaly  

Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2019
Gastroenteropancreatic tumors (GEPNETs) is a heterogeneous disease with variable clinical course. While promising therapeutic options exist for other adult cancers, there are no new molecular-based treatments developed for GEPNETs. One of the main targets of cancer immunotherapy is the Programmed Cell Death Ligand-1 (PD-L1) pathway.
Oktay, Esin, Yalcin, Gizem Donmez, Ekmekci, Sumeyye, Kahraman, Dudu Solakoglu, Yalcin, Abdullah, Degirmenci, Mustafa, Dirican, Ahmet, Altin, Zeynep, Ozdemir, Ozlem, Surmeli, Zeki, Diniz, Gulden, Ayhan, Semin, Bulut, Gulcan, Erdogan, Atike, Uslu, Ruchan   +14 more
openaire   +3 more sources

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer—Reply

JAMA Oncology, 2020
Zhijie, Wang, Zhengyi, Zhao, Jie, Wang
openaire   +2 more sources

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Cancer Control, 2022
Wei Yu, Junwei Su, Yunqing Qiu
exaly  

Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

Archives of Oral Biology, 2020
Liangjuan Fang, Hongzhi Quan, Sixuan Liu
exaly  

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung CancerA Systematic Review and Meta-Analysis of Trials

Chest, 2017
Monica Khunger, Nathan A Pennell, Adrián Vladimir Hernández   +2 more
exaly  

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

Histopathology, 2016
Dae-Seog Heo, Tae Min Kim, Yoon Kyung Jeon   +2 more
exaly  

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

European Journal of Cancer, 2014
Yih-leong Chang, Ching-yao Yang, Pan-chyr Yang   +2 more
exaly  

EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3

OncoImmunology, 2016
Dong-Wan Kim, Tae Min Kim, Bhumsuk Keam
exaly  

The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma

Leukemia and Lymphoma, 2020
Narittee Sukswai, Kitsada Wudhikarn, Chantiya Chanswangphuwana   +2 more
exaly